Wegovy Tablets vs Rybelsus: Not the Same Medicine

Written by the ClariDay clinical team. Medically reviewed by Ali Salih, GPhC-registered Pharmacist Independent Prescriber. Reviewed 18 July 2026. Next review 18 August 2027.

No. Rybelsus and Wegovy tablets are both semaglutide taken as a daily tablet, but they are two different medicines. Rybelsus is a diabetes treatment, licensed in the UK for type 2 diabetes at up to 14 mg a day. Wegovy tablets are licensed for weight management at up to 25 mg a day, and cannot be swapped for it.

Two oral semaglutide tablets are now sold in the UK. They are taken in almost the same way, and their names are easily confused, which is why people ask whether they are the same medicine.

Are they the same medicine?

No. In the UK a medicine is defined by what it is licensed to treat, and these two hold licences for different conditions.

Rybelsus and the Wegovy tablet are both semaglutide, the same GLP-1 medicine as the Wegovy and Ozempic injections, and both rely on an absorption enhancer called SNAC to survive the stomach. The active ingredient is identical.

Rybelsus is licensed to manage blood sugar in adults with type 2 diabetes, alongside diet and exercise. Its Summary of Product Characteristics describes it as "indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus" [1]. The Wegovy tablet was licensed separately: on 11 June 2026 the MHRA authorised oral semaglutide 25 mg for weight management, the first GLP-1 tablet licensed for weight loss in the UK [2].

Do the dose numbers tell you which is stronger?

No. It is tempting to read 25 mg as a stronger version of 14 mg, but the two doses were set for different conditions and were never meant to line up.

Rybelsus stops at 14 mg because that is as far as it needs to go for blood sugar [1]. Weight loss calls for a higher dose, so the Wegovy tablet continues up to 25 mg, climbing through 1.5 mg, 4 mg and 9 mg with at least a month at each step [2].

The numbers are not even fixed within Rybelsus. In August 2025 the MHRA warned that a newer, better-absorbed version using 1.5 mg, 4 mg and 9 mg strengths would run for a time alongside the older 3 mg, 7 mg and 14 mg one, and that "the two formulations will temporarily co-exist on the market, which may cause mix-ups," with a risk of overdosing [4].

A note from Ali Salih, Pharmacist Independent Prescriber.

“The thing I find myself counselling most carefully is that a dose number means very little on its own. The route a medicine is taken by can affect how it is absorbed, which means dosing can differ between formulations. A smaller figure on the box does not mean a weaker medicine. Comparing milligram numbers across different products is where misunderstandings can arise. I would not judge a medicine by its number alone, and I would not want a patient to either.”

Three common mix-ups, and what is actually true:

Can Rybelsus be used for weight loss?

Not as a licensed treatment. Using Rybelsus to lose weight means prescribing it outside its licence, which UK prescribers may do, but under tighter rules.

Official guidance says the prescriber must "be satisfied that there is a sufficient evidence base" for the use, and must give you enough information "to enable them to make an informed decision" [3]. Those requirements exist because, once a medicine is used outside what it was licensed for, more of the responsibility for safety sits with the prescriber and with you. Since there is now a tablet licensed and dosed for weight loss, off-label Rybelsus is rarely the sensible route to it.

How much weight might each one lead to?

In OASIS 4, the trial behind the weight-management licence, adults taking oral semaglutide 25 mg lost an average of 13.6% of their body weight over 64 weeks, against 2.2% on placebo; among those who kept to it the average was 16.6%, and about 30% lost at least a fifth of their weight [5, 6].

Rybelsus reduced weight by about 3.7 kg against 1.4 kg on placebo in its diabetes trials [1], the scale you would expect from a blood-sugar medicine.

Which one is right for you?

It usually comes down to what you are mainly treating.

If your main concern is type 2 diabetes, Rybelsus is the medicine for that, and any weight you lose is a bonus.

For weight loss without diabetes, the Wegovy tablet is the licensed option. Private eligibility follows the licence, broadly a body mass index of 30 or above, or 27 to 30 with a weight-related condition [2], and our guide on whether you are eligible for Wegovy tablets privately sets out the assessment.

If you have type 2 diabetes and weight loss is also a priority, the decision becomes more individual. Your blood sugar control, previous treatments, other conditions and long-term goals all shape which option fits, which is why it is worth deciding with a prescriber rather than alone.

Already on Rybelsus and considering the weight tablet? Treat it as a new decision rather than a dose increase. Moving between them means reassessing eligibility, restarting the dose titration and reviewing your goals, which our guide on switching from the Wegovy injection to tablets walks through.

What side effects should you expect?

Because both are semaglutide, the side effects are similar and mostly gut-related: nausea and changes in bowel habit that tend to be worst in the early weeks and ease as your body adjusts. In OASIS 4 these were usually mild to moderate, and few people stopped treatment because of them [5, 6].

A quick side-by-side

Sources for this table: [1], [2], [5], [6]. Figures are trial averages, not a promise of individual results.

In short

Work from your goal, not the dose on the box. A prescriber can match you to the medicine your goal needs, and check it is safe alongside the rest of your treatment.

If weight loss is your goal, you can book a consultation with a prescriber to check whether the Wegovy tablet is suitable for you.

Frequently asked questions

Is Rybelsus the same as the Wegovy pill?

No. Both are oral semaglutide, but Rybelsus is licensed for type 2 diabetes up to 14 mg a day, while the Wegovy tablet is licensed for weight management up to 25 mg a day [1, 2]. Same active ingredient, different licensed purpose and dose.

Can I take Rybelsus to lose weight?

Rybelsus is not licensed for weight loss in the UK, so using it for that would be off-label. A prescriber can only consider this if satisfied there is a sufficient evidence base and after giving you the information to make an informed decision [3]. For weight loss, the medicine licensed for the job is the Wegovy tablet, and the safest step is to discuss it with a prescriber.

Why is the Wegovy tablet 25 mg when Rybelsus is only 14 mg?

Because they are licensed for different purposes and dosed accordingly, and only a small fraction of an oral semaglutide dose is actually absorbed, which is why oral doses are far higher than the injection [7]. The numbers reflect different licensed jobs, not simply "stronger" versus "weaker."

Can I switch from Rybelsus to the Wegovy tablet by matching the dose?

No. You should never move between these products by matching milligram numbers, partly because Rybelsus itself now comes in two different-strength formulations that the MHRA has flagged as easy to confuse [4]. Any switch is a clinical decision made and monitored by a prescriber.

Are Rybelsus and the Wegovy tablet taken the same way?

Almost identically. Both are swallowed whole on an empty stomach with a small sip of water, after which you wait around 30 minutes before eating, drinking or taking other tablets [1]. That fasting routine is what lets oral semaglutide be absorbed at all.

This article is general information, not medical advice, and is not a substitute for a consultation with a qualified prescriber.

Related reading: Wegovy Tablets (Oral Semaglutide): The Complete UK Guide · What Is the Wegovy Pill and How Does It Work? · Wegovy Tablets: UK Price, Availability and How to Get Them

References

1. Novo Nordisk. (2025). Rybelsus 14 mg film-coated tablets: Summary of Product Characteristics (SmPC). electronic medicines compendium (emc). Accessed 18 July 2026. https://www.medicines.org.uk/emc/product/14389/smpc

2. Robinson, J. (2026, June 11). MHRA approves semaglutide oral tablets for weight loss. The Pharmaceutical Journal. Accessed 18 July 2026. https://pharmaceutical-journal.com/article/news/mhra-approves-semaglutide-oral-tablets-for-weight-loss

3. Medicines and Healthcare products Regulatory Agency. (2009, updated). Off-label or unlicensed use of medicines: prescribers’ responsibilities (Drug Safety Update). GOV.UK. Accessed 18 July 2026. https://www.gov.uk/drug-safety-update/off-label-or-unlicensed-use-of-medicines-prescribers-responsibilities

4. Medicines and Healthcare products Regulatory Agency. (2025, August 4). Rybelsus (oral semaglutide): Risk of medication error due to two co-existing formulations (Direct Healthcare Professional Communication). GOV.UK. Accessed 18 July 2026. https://assets.publishing.service.gov.uk/media/68dbb351dadf7616351e4c1d/DHPC_Letter-_Rybelsus_2G.pdf

5. Garvey, W. T., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2500969

6. American College of Cardiology. (2025, September 24). OASIS 4: Significant weight loss with oral semaglutide comparable with high-dose, SC versions. Accessed 18 July 2026. https://www.acc.org/latest-in-cardiology/journal-scans/2025/09/24/16/40/oasis-4

7. A peptide in a pill: Oral semaglutide in the management of type 2 diabetes. (2023). Diabetes, Metabolic Syndrome and Obesity. https://doi.org/10.2147/DMSO.S385196